Japanese based pharmaceutical company Shionogi & Co., Ltd (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi” or “the Company”) has launched its new European Headquarters in London, United Kingdom, to be called “Shionogi Limited”. The new headquarters will form a new era for the Company as it expands its global business into Europe.
As part of the 3rd Medium-Term Business Plan, a five year plan to expand its business world wide, Shionogi will bring a long standing reputation to Europe. Dating back from 1878, the Company has been involved in research, development, manufacturing and marketing activities for over 130 years and is very proud to be a part of the European pharmaceutical community.
Shionogi elected to base their European Headquarters in London following an extensive review of potential locations on the Continent as well as within the UK. London was chosen by Shionogi because of the good business infrastructure and support, the pool of exceptional talent, a favourable living environment for their employees and easy access to the rest of Europe. “We are delighted to be launching our new European Headquarters in London.” said Takashi Eakenoshita, CEOof Shionogi Europe. “We aim to achieve our mission as a company with a strong presence in Europe, which conducts business operations recognised by patients, their families, healthcare providers and broader communities.”
The Mayor of London, Boris Johnson, added “Boosting jobs and growth is my number one priority, and this means attracting ever more companies to the capital. Shionogi will make a fantastic addition to London's growing life sciences sector, which benefits from our top class universities and research centres, direct access to huge markets, a skilled cosmopolitan workforce, and fantastic connectivity. London really is the best place in the world to do business, something I will be taking every opportunity to showcase throughout this summer like no other.”
Shionogi has a strong heritage in the discovery and development of globally important therapies. In 1998 Shionogi licenced one of its new molecules that later became Crestor® (generic name: rosuvastatin calcium) to AstraZeneca, and still markets this drug in Japan today. Currently the Company has a strong strategic focus on infectious diseases, pain and metabolic syndrome.
The Company plans to quickly expand the number of employees in London and has recently made several key appointments: Dr Marco Renoldi, Dr Suhail Nurbhai, Dr Mark Sampson, Nina Strenitz and Joe Gaugas.
Shionogi marked its launch in Europe with a prestigious event in central London attended by key members of the pharmaceutical and healthcare industries, with talks from Lord Darzi of Denham PC KBE FMedSci HonFREng, (Imperial College London), Mr Martin Donnelly (Permanent Secretary for Business, Innovation and Skills ), Mr Kit Malthouse (Deputy Mayor for Business and Enterprise) Professor Andrea Genazzani, MD, PhD, FRCOG, (Professor of Obstetrics and Gynaecology, University of Pisa, Italy), Professor Brian Gazzard, CBE (Chelsea and Westminster Hospital, London) and Mr Isao Teshirogi, President and CEO of Shionogi.
Notes to Editors
About Shionogi & Co., Ltd.
Headquartered in Osaka, Japan, Shionogi & Co., Ltd. is a major research-driven pharmaceutical company dedicated to placing the highest value on patients. Shionogi’s Research and Development currently targets three therapeutic areas: Infectious Diseases, Pain, and Metabolic Syndrome. The Company has provided such innovative medicines as Crestor® and doripenem, which have been successfully delivered to millions of patients. In addition, Shionogi is engaged in new research areas such as allergy and cancer. Contributing to the health of patients around the world through development in these therapeutic areas is Shionogi’s primary goal. For more details, please visit www.shionogi.co.jp. For more information on Shionogi Limited, headquartered in London, United Kingdom, please contact +44 203 609 8660.
Forward Looking Statements
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The Company disclaims any intention or obligation to update or revise any forward looking statements whether as a result of new information, future events or otherwise.
For further information, contact: Kate Perry 0207 632 1896 or firstname.lastname@example.org